Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle
- 15 June 1994
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 57 (6) , 847-855
- https://doi.org/10.1002/ijc.2910570614
Abstract
The overt effects of the anti-cancer drugs cisplatin (cis-DDP) and taxol appear to be DNA modification and microtubule stabilization respectively, yet the mechanisms by which these drugs elicit tumor cell death are not well understood. In this report cell sensitivities to cis-DDP and taxol were accurately determined as a function of cell proliferation and cell cycle stage. Quiescent fibroblasts restimulated to synchronously enter the cell cycle become maximally sensitive to cis-DDP immediately preceding DNA synthesis, and resistance increases with onset of DNA synthesis. Mid-log proliferating cells were separated into progressive stages of the cell cycle by centrifugal elutriation or by double thymidine (dThd) block. Cells staged by either method are maximally sensitive to cis-DDP in G1, just prior to the onset of DNA synthesis and minimally sensitive in peak DNA synthesis, with entry into S phase resulting in a 2-fold decrease in sensitivity. Cells that remained blocked at the G1/S phase boundary during cis-DDP treatment remain maximally sensitive after release. Sensitivity to taxol increases at 2 points: transiently during transition of normal cells from quiescence to proliferation and steadily as proliferating cells progress from early G1 to late G2. This 3-fold increase in taxol sensitivity through the cell cycle is rapidly reversed upon cell division. Synchronous cells treated with either drug at points of maximum sensitivity initiate apoptotic DNA fragmentation 12-14 hr post-exposure to drug.Keywords
This publication has 26 references indexed in Scilit:
- Cisplatin induced cell killing and chromosomal aberrations in CHO cells: treated during G1 or S phaseMutation Research/DNA Repair, 1993
- Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53Published by Elsevier ,1992
- Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cellsJournal of Immunological Methods, 1992
- Mechanism of action of taxolTrends in Pharmacological Sciences, 1992
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 1991
- Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replicationBiochemistry, 1990
- Analysis of Events Associated With Cell Cycle Arrest at G2 Phase and Cell Death Induced by CisplatinJNCI Journal of the National Cancer Institute, 1990
- Clinical pharmacology of high-dose cisplatinCancer Chemotherapy and Pharmacology, 1985
- Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factorCell, 1981
- Maintaining perpetual synchrony in HeLa S3 cultureBiotechnology & Bioengineering, 1974